• Myeloma UK
  • Clinical Service Excellence Programme
Myeloma Academy
Sign inRegister
Menu
  • Home
  • CPD & Learning
    • Myeloma Nurse Learning Programme
    • My CPD Portfolio
    • Challenging Cases
    • Close
  • Library
    • Guidelines
      • Complications
      • COVID-19 guidance
      • General haemato/oncology
      • Imaging & Analysis
      • Management & Treatment
      • Palliative Care
      • Presentation & Diagnosis
      • Related conditions
      • Close
    • Patient Support and Information
    • Medical animations
    • Close
  • Resources
    • Myeloma Drug Finder
    • Myeloma Trial Finder
    • Assessment tools
    • Myeloma Spotlight
    • Primary care education
    • Secondary care education
    • Myeloma health economic model
    • Close
  • News & Events
    • News
    • Event calendar
    • Meeting highlights
    • Close
  • CSEP
  • About Us
    • Contact Us
    • Close
Menu back  
 

Current treatments

Subcutaneous bortezomib combined with weekly cyclophosphamide and dexamethasone is an efficient and well tolerated regime in newly diagnosed multiple myeloma.
Ong SY et al. Br J Haematol. 2014 Nov 21. doi: 10.1111/bjh.13238. [Epub ahead of print].

Plerixafor is superior to conventional chemotherapy for first-line stem cell mobilisation, and is effective even in heavily pretreated patients.
Clark RE et al. Blood Cancer J. 2014 Oct 31;4:e255. doi: 10.1038/bcj.2014.79.

Phase 2 study of bendamustine, bortezomib and dexamethasone as second-line treatment for elderly patients with multiple myeloma: the Intergroupe Francophone du Myelome 2009-01 trial.
Rodon P et al. Haematologica. 2014 Nov 14. pii: haematol.2014.110890. [Epub ahead of print].

Overall survival of relapsed and refractory multiple myeloma patients after adjusting for crossover in the MM-003 trial for pomalidomide plus low-dose dexamethasone.
Morgan G et al. Br J Haematol. 2014 Nov 18. doi: 10.1111/bjh.13227. [Epub ahead of print].

Impact of early use of lenalidomide and low-dose dexamethasone on clinical outcomes in patients with relapsed/refractory multiple myeloma.
Kobayashi T et al. Int J Hematol. 2014 Nov 11. [Epub ahead of print].
Efficacy and safety of long-term treatment with lenalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma.
Dimopoulos MA et al. Blood Cancer J. 2014 Nov 7;4:e257. doi: 10.1038/bcj.2014.77
  • Guidelines
  • Patient Support and Information
  • Medical animations
Bottom menu

Charity No. SC 026116
Myeloma UK
22 Logie Mill
Beaverbank Business Park
Edinburgh
EH7 4HG